Pharmaceuticals News and Research

RSS

Vaccine lawsuit rejected by Supreme Court

The U.S. Supreme Court ruled on Tuesday against the parents of Hannah Bruesewitz, 18, who suffered seizures and permanent brain damage after receiving a diptheria-tetanus-pertussis (DTP) vaccine in 1993. The Bruesewitz family had sued Wyeth who was then the parent company of the maker of the DTP vaccine that Hannah received as an infant.

27 Feb 2011

Takeda receives Japanese approval for additional indications for NESINA

Furiex Pharmaceuticals, Inc. today confirmed that Takeda Pharmaceutical Company Limited's applications for two additional indications for "NESINA®" (alogliptin), combination therapy with sulfonylurea and combination therapy with biguanide for type 2 diabetes, were approved by the Japanese Ministry of Health, Labour and Welfare.

25 Feb 2011

Neoprobe's Lymphoseek Phase 2 study data published in Annals of Surgical Oncology

Neoprobe Corporation (NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that results from a Phase II study of Lymphoseek® (Tilmanocept) have been published online in the Annals of Surgical Oncology and demonstrate the tracing agent's ability to identify tumor-draining lymph nodes in breast cancer and melanoma patients.

25 Feb 2011

Medwell commits $2,000,000 investment in Mimetogen

Medwell Capital Corp. today announced that it has committed to invest up to $2,000,000 in Mimetogen Pharmaceuticals Inc. ("Mimetogen"), a privately-held, clinical-stage company developing a treatment for dry eye disease. Medwell Capital participated in a Series B equity financing with existing Mimetogen investors, iNovia Capital, MSBi Valorisation and VIMAC Milestone Medica.

25 Feb 2011

U.S.-Chile collaborate to study new long-acting local anesthetic derived from algae

A U.S.-Chile collaboration is bringing surgical patients closer to having a long-acting local anesthetic. In a randomized, double-blind trial, patients given neosaxitoxin, a new local anesthetic derived from algae, had significantly less postoperative pain and recovered about two days sooner than those given the commonly used local anesthetic bupivacaine.

25 Feb 2011

Warner Chilcott fourth quarter revenue increases 1% to $694.4 million

Warner Chilcott plc today announced its results for the quarter and year ended December 31, 2010. As discussed more fully below, our financial position and results of operations in the quarter ended December 31, 2010 as compared to the prior year quarter were significantly impacted by several important transactions in 2009 and 2010.

25 Feb 2011

AMAG fourth quarter total revenues increase to $17.2 million

AMAG Pharmaceuticals, Inc. a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2010.

25 Feb 2011

Savient launches KRYSTEXXA in the U.S.

Savient Pharmaceuticals, Inc. announced the official full U.S. commercial launch of KRYSTEXXA™ (pegloticase), which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic gout in adult patients refractory to conventional therapy. KRYSTEXXA is now the first and only therapy available to address this unmet medical need.

25 Feb 2011

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001.

25 Feb 2011

Research sheds new light on problem of insulin resistance in type 2 diabetes

A research team, led by La Jolla Institute scientist Joel Linden, Ph.D., has shed new light on the problem of insulin resistance, and identified the key participants in a molecular pathway that holds therapeutic promise for reducing the severity of type 2 diabetes.

25 Feb 2011

Scientists find p27Kip1 protein expression in adult and aged human inner ear

In collaboration with scientists and clinicians from the University of California Los Angeles, scientists from Sound Pharmaceuticals have found p27Kip1 to be expressed in the adult and aged human inner ear including the auditory and vestibular sensory organs.

25 Feb 2011

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.

25 Feb 2011

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.

25 Feb 2011

BioCryst receives HHS contract to complete peramivir Phase 3 study in patients with influenza

BioCryst Pharmaceuticals, Inc. announced that it has been awarded a $55.0 million contract modification by the U.S. Department of Health & Human Services intended to fund to completion the Phase 3 development of its neuraminidase inhibitor, intravenous peramivir, for the treatment of patients hospitalized with influenza.

25 Feb 2011

Thermo Fisher to sell Athena Diagnostics and Lancaster Labs businesses for $940 million

Thermo Fisher Scientific Inc., the world leader in serving science, announced today that it has signed definitive agreements to sell its Athena Diagnostics and Lancaster Laboratories businesses for a total of $940 million in cash.

From Thermo Fisher Scientific Inc. 24 Feb 2011

BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD

BioSante Pharmaceuticals, Inc. today announced that enrollment of subjects in the first of two pivotal Phase III LibiGel safety and efficacy trials has been completed.

24 Feb 2011

PhRMA: 460 medicines in development for rare diseases

America's biopharmaceutical research companies are intensifying research into rare diseases, which often are among the most devastating to patients and complex for researchers. A record 460 medicines for rare diseases are in late stages of the pipeline, either in clinical trials or awaiting Food and Drug Administration (FDA) review, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

24 Feb 2011

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Isis Pharmaceuticals, Inc. announced today the results from a Phase 1 clinical trial in which ISIS-CRPRx produced statistically significant reductions in C-reactive protein in the cohort of subjects in the study with elevated CRP.

24 Feb 2011

Supreme Court raises the bar for suits against vaccine producers

The decision, announced Tuesday, will make it harder for parents who maintain that their children were injured by vaccines to file lawsuits against drug makers. Public health advocates say the ruling will help maintain the nation's vaccine supply levels.

24 Feb 2011

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in a Phase 3 randomized, double-blind, placebo-controlled trial evaluating Nexavar tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.

24 Feb 2011

Pharmaceuticals News and Research

Vaccine lawsuit rejected by Supreme Court

Takeda receives Japanese approval for additional indications for NESINA

Neoprobe's Lymphoseek Phase 2 study data published in Annals of Surgical Oncology

Medwell commits $2,000,000 investment in Mimetogen

U.S.-Chile collaborate to study new long-acting local anesthetic derived from algae

Warner Chilcott fourth quarter revenue increases 1% to $694.4 million

AMAG fourth quarter total revenues increase to $17.2 million

Savient launches KRYSTEXXA in the U.S.

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Research sheds new light on problem of insulin resistance in type 2 diabetes

Scientists find p27Kip1 protein expression in adult and aged human inner ear

Salix anticipates receipt of FDA's CRL for XIFAXAN 550 mg sNDA

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

BioCryst receives HHS contract to complete peramivir Phase 3 study in patients with influenza

Thermo Fisher to sell Athena Diagnostics and Lancaster Labs businesses for $940 million

BioSante completes patient enrollment in LibiGel Phase III trial for treatment of FSD

PhRMA: 460 medicines in development for rare diseases

Isis Pharma announces ISIS-CRPRx Phase 1 trial results in diseases with elevated CRP

Supreme Court raises the bar for suits against vaccine producers

Onyx, Bayer initiate patient enrollment in Nexavar Phase 3 trial for breast cancer treatment

Pittcon Highlights: Pharmaceutical & Biologic eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence